Stockreport

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition [Yahoo! Finance]

Rigel Pharmaceuticals, Inc.  (RIGL) 
Last rigel pharmaceuticals, inc. earnings: 2/27 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.rigel.com
PDF RBC-TI/HI-E responses occurred in 40% of evaluable TD patients receiving R289 doses =500 mg QD SOUTH SAN FRANCISCO, Calif. Dec. 9, 2024 /PRNewswire/ -- Rigel Pharmace [Read more]